Ramoni, Davide
Coco, Simona
Rossi, Giovanni
Dellepiane, Chiara
Bennicelli, Elisa
Santamaria, Sara
Zinoli, Linda
Tagliafico, Alberto Stefano
Tagliamento, Marco
Barletta, Giulia
Liberale, Luca
Tirandi, Amedeo
Minetti, Silvia
Bertolotto, Maria
Montecucco, Fabrizio
Genova, Carlo
Carbone, Federico
Funding for this research was provided by:
Ministero della Salute (2754291)
Università degli Studi di Genova
Università degli Studi di Genova
Article History
Received: 24 November 2023
Accepted: 26 January 2024
First Online: 13 March 2024
Declarations
:
: Carlo Genova declares honoraria from Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Merck-Sharp-Dohme, Novartis, Roche, Sanofi, Takeda. Luca Liberale is co-inventor on the international patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies which specifically bind IL-1α to reduce various sequelae of ischaemia–reperfusion injury to the central nervous system. Luca Liberale reports speaker fees from Daiichi-Sankyo outside the submitted work, he is counsellor of the European Society for Clinical Investigation and has received fundings from the Novartis Foundation for Medical-biological Research, the Swiss Heart Foundation, the Italian Ministry of Health (unrelated to this work). The other authors declare they have no conflict of interest.